CHFS HFU Header
Subodh Verma

Subodh Verma

MD, PhD, FRCSC, FAHA
Cardiac Surgeon, St Michael’s Hospital, Unity Health Toronto
Scientist, Keenan Research Centre for Biomedical Science and Li Ka Shing
Knowledge Institute of Unity Health Toronto
Professor of Surgery and Pharmacology & Toxicology, University of Toronto
Canada Research Chair in Cardiovascular Surgery
Toronto, ON
Biography

Dr. Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto. He is the Canada Research Chair in Cardiovascular Surgery and a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He previously served as the Canada Research Chair in Atherosclerosis (2007-2017). He is an appointee of the American Association of Thoracic Surgeons (AATS) and a member of the College of New Scholars, Artists and Scientists, Royal Society of Canada. According to Google Scholar in December 2020, Dr. Verma has an h-index of 107 and his work has been cited over 58,000 times.

Dr. Verma has published extensively in prestigious journals like the NEJM, Lancet, Circulation, JACC, Nature, and JCI and he is currently an Associate Editor of the European Heart Journal. Dr Verma is an active contributor to Canadian clinical practice guidelines and recently co-authored the recommendations for atrial fibrillation, antiplatelet therapy, heart failure and diabetes; he was a member of the 2018 AATS consensus guidelines committee on bicuspid aortic valve-related aortopathy. Dr. Verma has served in various capacities on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008.

Dr. Verma has leadership roles on 7 global heart failure trials in diabetes – DAPA-HF, DELIVER, DETERMINE-A, DETERMINE-B, EMPEROR-Preserved, EMPEROR-Reduced and SOLOIST-WHF. He is also involved in the DAPA ACT HF-TIMI 68, FINEARTS-HF, STEP HFpEF, VESALIUS-CV, DARE-19, SELECT and CLEAR SYNERGY trials. He founded and oversees the CardioLink platform at St Michael’s Hospital that is conducting cardiometabolic and surgically oriented RCTs and translational studies.

Dr. Verma leads a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiovascular and cardiometabolic disease as well as answer timely and relevant healthcare questions. His research has yielded 2 United States patents and is supported by several national peer-reviewed grants.

 

Follow @CanHFSociety Along on Twitter

#HFUpdate